

CDRH3 as set forth in SEQ ID NO: 24, and a VL domain comprising a CDRL1 as set forth in SEQ ID NO: 25, a CDRL2 as set forth in SEQ ID NO: 26, and a CDRL3 as set forth in SEQ ID NO: 27;

(C) a VH domain comprising a CDRH1 as set forth in SEQ ID NO: 44, a CDRH2 as set forth in SEQ ID NO: 45, and a CDRH3 as set forth in SEQ ID NO: 46, and a VL domain comprising a CDRL1 as set forth in SEQ ID NO: 47, a CDRL2 as set forth in SEQ ID NO: 48, and a CDRL3 as set forth in SEQ ID NO: 49; or

(D) a VH domain comprising a CDRH1 as set forth in SEQ ID NO: 66, a CDRH2 as set forth in SEQ ID NO: 67, and a CDRH3 as set forth in SEQ ID NO: 68, and a VL domain comprising a CDRL1 as set forth in SEQ ID NO: 69, a CDRL2 as set forth in SEQ ID NO: 70, and a CDRL3 as set forth in SEQ ID NO: 71,

each according to Kabat numbering.

**63.** The recombinant antibody or antigen binding fragment thereof of claim **61**, wherein

(A) the VH domain is set forth in SEQ ID NO: 18 and the VL domain is set forth in SEQ ID NO: 21;

(B) the VH domain is set forth in SEQ ID NO: 30 and the VL domain is set forth in SEQ ID NO: 33;

(C) the VH domain is set forth in SEQ ID NO: 57 and/or the heavy chain is set forth in SEQ ID NO: 55; and the VL domain is set forth in SEQ ID NO: 65 and/or the light chain is set forth in SEQ ID NO: 63;

(D) the VH domain is set forth in SEQ ID NO: 79 and/or the heavy chain is set forth in SEQ ID NO: 77; and the VL domain is set forth in SEQ ID NO: 87 and/or the light chain is set forth in SEQ ID NO: 85.

\* \* \* \* \*